A Cost-Effectiveness Approach To Drug Subsidy And Pricing In Australia

The Australian government offers its citizens subsidies on a select list of pharmaceuticals. For a drug to qualify for inclusion on this list, its manufacturer must demonstrate that the drug is both clinically effective and cost-effective. In part, this measure, along with others, was introduced to...

Full description

Saved in:
Bibliographic Details
Published in:Health Affairs 2001-05, Vol.20 (3), p.104-114
Main Authors: Birkett, Donald J, Mitchell, Andrew S, McManus, Peter
Format: Article
Language:English
Subjects:
Australia
Committees
Cost analysis
Cost control
Cost Sharing
Cost-Benefit Analysis
Decision making
Drug Approval
Drug Costs
Drug dosages
Drug Industry - organization & administration
Evidence-Based Medicine
Financing, Government
Formularies as Topic
Government subsidies
Health Services Accessibility - organization & administration
Hospitals
Humans
Industrialized nations
Marketing
National Health Programs - organization & administration
Outcome Assessment (Health Care)
Patients
Pharmaceutical industry
Prescription drugs
Rate Setting and Review
Statistical analysis
Studies
Subsidies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Australian government offers its citizens subsidies on a select list of pharmaceuticals. For a drug to qualify for inclusion on this list, its manufacturer must demonstrate that the drug is both clinically effective and cost-effective. In part, this measure, along with others, was introduced to improve clinical and economic outcomes. Although this evidence-based system has provided transparency and consistency in decision making about which drugs will be covered, it may not have contained the rate of increase in drug costs.
ISSN:0278-2715
1544-5208
2694-233X
DOI:10.1377/hlthaff.20.3.104